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Polychlorinated biphenyls (PCBs) are syn-
thetic compounds containing a biphenyl moi-
ety substituted with 1–10 chlorine atoms
(209 possible congeners). PCBs were synthe-
sized and sold as congener mixtures character-
ized by their chlorine content (1). Their
chemical and thermal stability made them
suitable for diverse industrial applications, but
their resistance to metabolic degradation con-
tributed to their persistence in the environ-
ment and their biomagnification in food
chains all over the world. Despite the ban on
production, sale, and import of PCBs into
North America since 1978, animal and
human populations are still being exposed to
these compounds (2,3), even in areas far away
from industrial sources, due to long-range
atmospheric and oceanic transport (4,5). 
Prenatal exposure to PCBs has been
linked to adverse developmental effects in
human populations exposed accidentally
(6–10), occupationally (11), and environ-
mentally (12–19) to these compounds. The
underlying mechanisms of these toxic effects
have not been fully elucidated, but several
lines of evidence suggest that the mechanism
may involve altered signaling in pathways
modulated by the aryl hydrocarbon receptor
(AhR) (20,21). AhR ligands include poly-
cyclic aromatic hydrocarbons (PAHs), 
polychlorodibenzo-p-dioxins (PCDDs),
polychlorodibenzofurans (PCDFs), coplanar
PCBs [International Union of Pure and
Applied Chemistry (IUPAC) numbers, 77,
81, 126, and 169], and mono-ortho-substi-
tuted PCBs (PCBs 105, 114, 118, 123, 156,
157, 189) (22,23). Binding of these com-
pounds to the AhR activates the receptor,
which in turns binds to DNA and regulates
the expression of several genes (potentially
mediating toxicity), including cytochrome
P450 1A1 (CYP1A1) (24,25). 
CYP1A1 induction was previously used as
a biomarker of environmental exposure to
AhR agonists (mostly PAHs) in animal (26)
and human (27,28) populations. Placental
CYP1A1 induction was also reported in
women who smoked during pregnancy
(29–32). In addition, CYP1A1 induction was
suggested as a biomarker of adverse develop-
mental effects. In a study by Pelkonen et al.
(33), newborns from smokers with high pla-
cental aryl hydrocarbon hydroxylase (AHH)
activity (CYP1A1-related) had lower birth
weights than newborns from smokers with
lower placental AHH activity. CYP1A1 activ-
ity (AHH) was also 100-fold higher in
Taiwanese women with Yu-Cheng syndrome
(which resulted from high-level exposure to
PCBs and their degradation by-products,
such as PCDFs) than in Taiwanese and
American women exposed to background
levels of these compounds (6). Placental
CYP1A1 activity (AHH) in Taiwanese
women with Yu-Cheng syndrome was also
about 10-fold higher than in American
women exposed to background levels of
organochlorines who smoked during preg-
nancy (6). In addition, an inverse correlation
of ethoxyresorufin-O-deethylase (EROD)
and AHH enzyme activities to birth weight
was subsequently reported in Yu-Cheng
patients (34). These results indicated that
accidental exposure to PCBs and PCDFs
induced placental CYP1A1 activity and fur-
ther suggested a relation between placental
CYP1A1 activity and adverse developmental
effects. However, the effects of an environ-
mental exposure to PCBs and other AhR
agonists on placental CYP1A1 activity has
yet to be investigated in populations exposed
through dietary intake.
The Inuit population of Nunavik (north-
ern Québec, Canada) is exposed to unusually
high doses of PCBs and other organochlo-
rines due to their consumption of a tradi-
tional diet that includes large quantities of sea
mammal fat (35–40). Concentrations of
PCBs in breast milk were 5-fold greater in
the Nunavik population than in populations
from southern Québec (41). The difference
between plasma concentrations of dioxin-like
compounds in Inuit adults and southern
Québec adults was even more pronounced
[184 ng toxic equivalents (TEQ)/kg lipid vs.
26 ng TEQ/kg lipid], and TEQs were mostly
accounted for by PCBs in the Inuit popula-
tion (35). The present investigation was part
of a cohort study addressing child develop-
ment in Nunavik Inuit. The objective was to
investigate the distribution of PCBs in the
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Some polychlorinated biphenyl (PCB) congeners are CYP1A1 inducers, and induction of this
enzyme in the placenta has been linked to adverse effects on fetal development. The objective of
this study was to determine if the body burden of PCBs is related to placental CYP1A1 activity in
Inuit women from Nunavik (northern Québec), a population highly exposed to organochlorines.
Placenta and cord blood samples were obtained from 35 Inuit women and 30 women from a
southern Québec community exposed to background levels of organochlorines. We measured
PCB concentrations in all cord plasma samples and in a subset of placenta samples from the
Nunavik group and assessed CYP1A1 activity (ethoxyresoruﬁn-O-deethylase; EROD) in placental
microsomes from all participants. Concentrations of PCBs in cord plasma were strongly corre-
lated to those in placenta (Pearson’s r = 0.77–0.97, p < 0.001) and were on average 4-fold higher
in Inuit women than in southern Québec women [for PCB 153, the geometric means (geometric
SDs) were 83.3 (1.9) ng/g lipid vs. 16.9 (1.6) ng/g lipid, respectively]. Despite this difference in
PCB body burden, both study groups had similar EROD activities when data were stratified
according to tobacco smoking. Although simple correlation analysis first showed that placental
EROD activity was correlated with PCB 153 plasma concentration in the Nunavik group, a mul-
tivariate analysis failed to demonstrate a signiﬁcant contribution of PCBs to EROD activity when
tobacco smoking was included in the analysis. We conclude that dietary exposure to PCBs in
Inuit women from Nunavik does not signiﬁcantly inﬂuence EROD activity in the placenta, impli-
cating tobacco smoking as the major modulating factor. Key words: CYP1A1, Inuit, placenta,
polychlorinated biphenyl, tobacco smoke. Environ Health Perspect 110:607–612 (2002). [Online
29 April 2002]
http://ehpnet1.niehs.nih.gov/docs/2002/110p607-612pereg/abstract.htmlfetal–placental unit and the relationship
between PCB exposure and CYP1A1 activity
in placental tissue from Inuit women in
Nunavik. Tobacco smoking during preg-
nancy was assessed because of its potential
confounding effect on CYP1A1 induction.
Materials and Methods
Population description and sampling. Thirty-
ﬁve Inuit women residing in Nunavik were
recruited upon entering Kuujjuaq hospital to
give birth. Thirty white women were also
recruited in a southern Québec population
(Sept-Iles) exposed to background levels of
organochlorines (42). After thorough expla-
nation of the project and after signing a con-
sent form, women answered a questionnaire
addressing smoking and dietary habits and
gave their consent to placental and umbilical
cord blood sampling. The southern Québec
group comprised 15 smokers and 15 non-
smokers; the Nunavik group comprised 23
smokers and 12 nonsmokers (based on self-
declared cigarette smoking during preg-
nancy). Maternal smoking status was
ascertained using cotinine content in meco-
nium (32,43) in order to adequately control
for the potential confounding effect of
tobacco smoke-related placental CYP1A1
induction (29–33). 
Umbilical cord blood samples (30 mL)
were collected in vacutainers containing
EDTA as the anticoagulant and centrifuged,
and the plasma was transferred to glass vials
prewashed with hexane. Plasma samples
were stored at –20°C until analysis. Placentas
were collected within 1 hr after delivery.
Connective tissue and blood vessels were
removed, and then 10-g samples were cut
and frozen at –80°C in polycarbonate vials
until they were shipped to the laboratory on
dry ice. Meconium was collected from the
diaper, transferred into a 50-mL conical tube,
and kept frozen at –20°C until analysis. 
Cotinine determination in meconium. We
extracted cotinine from meconium according
to the procedure developed by Lewis (44).
Meconium samples were homogenized in
glacial acetic acid and acetone/diphenylamine
solution (1:2). The solvents were evaporated
and the residue dissolved in phosphate buffer
(60 mM, pH 6.0). Cotinine was extracted by
solid-phase extraction and measured by mass
spectrometry. The detection limit for coti-
nine in meconium was 5 ng/g dry weight,
and the coefficient of variation was 8.8%
(based on seven analyses of the same sample).
Average recoveries varied from 95% to
122% in spiked samples. We reassigned par-
ticipants to the appropriate smoking cate-
gory (nonsmokers, moderate, and heavy
smokers) based on the cotinine content of
meconium samples and on cut-off values
determined previously (< 5 ng/g, 5 to < 86
ng/g, ≥ 86 ng/g) (32). 
Analyses of PCBs in plasma and placenta
samples. We measured PCBs in all umbilical
cord plasma samples from both groups and
in a subset of placental samples from the
Nunavik group (n = 20). Extraction of
plasma samples (2 mL) was carried out with
ammonium sulfate:ethanol:hexane (1:1:3).
Extracts were concentrated and purified by
chromatography on Florisil columns. Lipids
were extracted from placental tissue with ace-
tone:hexane (2:1). An aliquot of the organic
fraction was evaporated to constant weight
for the gravimetric determination of the lipid
content. The remaining organic fraction was
washed with concentrated sulfuric acid, dis-
tilled water, and potassium hydroxide and
concentrated under vacuum. The extracts
were then purified by chromatography on
acidified silica gel and Florisil columns.
Fourteen PCB congeners (PCBs 28, 52, 99,
101, 105, 118, 128, 138, 153, 156, 170,
180, 183, 187) were measured in the plasma
and placenta extracts by high-resolution gas
chromatography with electron capture detec-
tion. PCB analyses were carried out using an
HP-5890 series II gas chromatograph
equipped with dual-capillary columns (Ultra-
1 and Ultra-2, Hewlett Packard, Palo Alto,
CA, USA) and dual Ni-63 electron-capture
detectors (Hewlett Packard). Using a com-
puter program developed in-house, we iden-
tiﬁed peaks by their relative retention times
obtained on the two columns. 
Total cholesterol, free cholesterol, and
triglycerides were measured in plasma samples
by standard enzymatic procedures, and
phospholipids were determined according to
the enzymatic method of Takayama et al.
(45), using a commercial kit (Wako Pure
Chemical Industries, Richmond, VA). We
estimated the concentration of total plasma
lipids according to the formula developed by
Phillips et al. (46). 
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Table 1. Characteristics of participants.
Southern Québec Nunavik
Characteristic Percent Meana SD No. Percent Meana SD No. p-Valueb
Maternal
Age (year) – 25.9 5.2 30 – 24.2 7.1 35 0.264
Weight before pregnancy (kg) – 59.7 11.6 30 – 59.8 13.6 25 0.960
Smoked during pregnancy (%) 50.0 – – 30 65.7 – – 35 0.219
Cigarettes per day during pregnancyc – 11.7 6.6 15 – 12.6 9.2 23 0.742
Parity (percent primiparous) 36.6 – – 30 11.4 – – 35 0.020
Newborn
Male (%) 46.6 – – 30 34.2 – – 35 0.325
Weight (kg) – 3.33 0.49 30 – 3.44 0.44 33 0.343
Length (cm) – 50.9 2.1 30 – 50.1 2.4 33 0.737
aArithmetic mean. bp-Value for Student’s t-test (comparison of means) or Fisher’s exact test (comparison of proportions). cAmong smokers; one nonsmoker in each group reported
smoking before pregnancy (ﬁve cigarettes/day).
Table 2. PCB concentrations (ng/g plasma lipids) in umbilical cord plasma from southern Québec and
Nunavik groups. 
Southern Québec (n = 30) Nunavik (n = 35)
Congener Cl position GM (GSD)a Percent detected GM (GSD) Percent detected
PCB 28 2,4,4´ < LODb  6.7 < LOD 0
PCB 52 2,2´5,5´ < LOD 30 < LOD 43
PCB 99 2,2´,4,4´,5 5.7 (1.5) 50 18.9 (1.8) 97
PCB 101 2,2´,4,5,5´ 9.7 (2.1) 63 7.7 (1.8) 63
PCB 105 2,3,3´,4,4´ < LOD 3.3 < LOD 20
PCB 118 2,3´,4,4´,5 < LOD 40 16.7 (1.8) 97
PCB 128 2,2´,3,3´,4,4´ < LOD — < LOD 0
PCB 138 2,2´,3,4,4´,5´ 12.7 (1.6) 93 58.4 (1.9)* 100
PCB 153 2,2´,4,4´,5,5´ 16.9 (1.6) 97 83.3 (1.9)* 100
PCB 156 2,3,3´,4,4´,5 < LOD — < LOD 40
PCB 170 2,2´,3,3´,4,4´,5 < LOD 10 10.4 (2.3) 71
PCB 180 2,2´,3,4,4´,5,5´ 7.2 (1.6) 67 31.8 (2.0) 100
PCB 183 2,2´,3,4,4´,5´,6 < LOD 13 6.5 (1.6) 51
PCB 187 2,2´,3,4´,5,5´,6 < LOD 17 18.4 (1.8) 97
aCalculated for congeners detected in > 50% of samples. bMean value below the limit of detection (LOD; range, 5–8 ng/g
plasma lipids). *p < 0.001; Student’s t-tests conducted for congeners detected in > 70% of samples.Quality control was performed using the
SRM-1588 standard (National Institute of
Standards and Technology, Gaithersburg,
MD, USA). In placental samples, percent
recovery ranged between 74% and 106% for
all PCB congeners (n = 3). The detection
limit for PCB congeners ranged between 2.3
and 4.1 ng/g lipids. Coefﬁcients of variation
were between 9.1% and 29.9%, and biases
ranged from –23.4% to +5.6%, based on 20
determinations. In plasma samples, percent
recoveries were > 92%, and the detection
limit was 0.02 µg/L for all congeners.
Coefficients of variation ranged from 2.1%
to 7.5%, and bias ranged from –10.9% to
+3.0%. PCB analyses were carried out by the
laboratory of the Institut National de Santé
Publique du Québec, which is accredited by
the Canadian Association for Environmental
Analytical Laboratories.
Determination of CYP1A1 enzyme activ-
ity. Microsomal fractions were isolated from
placental tissue by differential centrifugation
and stored in Tris-sucrose buffer (50 mM
Tris-0.25 M sucrose, pH 8.0) at –80°C until
further processing. We assayed EROD activ-
ity in 96-well plates with simultaneous pro-
tein quantification using fluorescamine
labeling, according to a modification of a
method described previously (47,48). Each
sample was analyzed in quadruplicate (2 × 25
µL and 2 × 10 µL microsomes) and assayed
on different plates. We used microsomes
from cells expressing CYP1A1 (Gentest
Corp., Woburn, MA, USA) as positive con-
trols, and analyzed six blank wells on each
plate to determine the detection limit of
resoruﬁn and ﬂuorescamine ﬂuorescence. We
always performed a dual standard curve of
bovine serum albumin and resoruﬁn on each
plate. EROD activity was expressed in pico-
moles of resorufin formed per minute per
milligram of microsomal proteins.
Statistical analyses. PCB plasma concen-
trations and EROD activity did not follow a
normal distribution, and these variables were
normalized through a logarithmic conversion
(log10) before further processing. A value equal
to one-half the detection limit was attributed
to samples below the detection limit. We cal-
culated geometric means (GMs) and standard
deviations (GSDs) for congeners detected in
> 50% of samples. Statistical testing was con-
ducted for congeners detected in > 70% of
samples. We compared means using Student’s
t-tests and compared proportions by Fisher’s
Exact tests. Correlations between concentra-
tions of PCBs were tested using Pearson
correlation coefficients, whereas Spearman
correlation coefﬁcients were used to test corre-
lations involving cotinine concentration in
meconium. Analyses of variance or covariance
were carried out to test the effect of PCB
exposure and smoking on EROD activity. For
all analyses, the level of signiﬁcance (α) was
0.05. All statistical tests were performed using
the SPSS 8.0 for Windows statistical package
(SPSS Inc., Chicago, IL, USA).
Results
Among all maternal and newborn character-
istics listed in Table 1, only parity differed
between groups. There were fewer primi-
parous women in the Inuit group than in the
southern Québec group (p = 0.02). Birth
weight was similar in both groups, but when
data were stratiﬁed by smoking status, mean
birth weight of newborns from smokers was
lower than that from nonsmokers by an
average of 359 g in the southern Québec
group (p = 0.04) and 272 g in the Nunavik
group (p = 0.16). 
Most PCB congeners were detected more
frequently in plasma samples from the
Nunavik group than in those from the south-
ern Québec group (Table 2). PCB 138 and
PCB 153 were detected in > 90% of samples
in both groups, and their plasma concentra-
tions were on average 4-fold higher in the
Nunavik group than in the southern Québec
group. Other congeners detected in > 50% of
samples in the Nunavik group were PCBs
99, 101, 118, 170, 180, 183, and 187.
PCB analyses in placental samples from
the Nunavik group (n = 20) revealed lower
concentrations in placenta than in umbilical
Children’s Health • PCB exposure and placental CYP1A1
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Figure 1. Concentrations of PCB congeners in umbilical cord plasma and placental samples in a subset of the
Nunavik group (n = 20). Bars represent the GM and GSD. 
*Statistically signiﬁcant difference between placental and plasma concentrations.
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Table 3. Correlations between concentrations of PCB congeners in umbilical cord plasma and placenta in
a subsample of the Nunavik group (n = 20).
Plasma Placenta
Congener ra (% detected) (% detected)
PCB 99 0.89 100 100
PCB 118 0.83 100 100
PCB 138 0.96 100 100
PCB 153 0.96 100 100
PCB 170 0.91 75 90
PCB 180 0.97 100 100
PCB 183 0.77 75 85
PCB 187 0.88 100 100
aPearson’s correlations for congeners detected in > 70% of plasma and placenta samples. All correlation coefficients
were statistically signiﬁcant (p < 0.001).
Figure 2. Correlation between PCB 153 concentra-
tions in placenta and umbilical cord plasma in a
subset of the Nunavik group (n = 20).
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0 100 200 300 400 500cord plasma. This observation was particularly
striking for highly persistent congeners 138,
153, and 180, as well as for mono-ortho-sub-
stituted congener 118, which were all 1.5- to
2-fold lower in placenta than in umbilical
cord plasma (Figure 1). PCB concentrations
in placenta were highly correlated with those
in umbilical cord plasma, and correlation
coefficients ranged from 0.77 to 0.97 (p <
0.001) for all congeners detected in > 70% of
samples (Table 3). Figure 2 illustrates the cor-
relation for PCB 153. Correlations among
PCBs congeners detected in > 70% of umbili-
cal cord plasma samples from Nunavik are
shown in Table 4. PCB concentrations were
strongly intercorrelated (Pearson’s r > 0.75, p
< 0.001). In particular, the highly persistent
congener PCB 153 was strongly correlated
with other frequently detected PCB con-
geners in the Nunavik group, including PCB
118, a known AhR agonist. Hence PCB 153
is a good predictor of all major PCB con-
geners found in umbilical cord plasma sam-
ples from the Nunavik group. Furthermore,
in view of the strong correlation noted above
between PCB 153 concentrations in plasma
and placenta (Figure 2), we selected PCB 153
concentration in umbilical cord plasma as the
exposure variable in further statistical analyses
involving placental biomarkers. 
We assessed CYP1A1 activity (EROD) in
placental microsomes. EROD activity levels
[GM (GSD)] in the southern Québec and
Nunavik groups were 6.1 (3.6) and 4.6 (3.6)
pmol resoruﬁn/min/mg protein, respectively.
A statistically signiﬁcant correlation of placen-
tal EROD activity to PCB 153 plasma con-
centration was observed in the Nunavik group
(Pearson’s r = 0.38, p = 0.02), but not in the
southern Québec group (p = 0.69). Placental
EROD activity was also significantly corre-
lated with cotinine concentration in meco-
nium in the Nunavik group (Spearman’s r =
0.80, p < 0.001), as well as in the southern
Québec group (r = 0.78, p < 0.001). 
Table 5 shows the number of participants
in each smoking category before and after
reclassiﬁcation based on the concentration of
cotinine in meconium samples. Several
women from both groups were reclassiﬁed in
appropriate smoking categories based on cut-
off values determined previously (32). Figure
3 presents EROD activities in both groups
according to these smoking categories. The
mean value in moderate smokers was approx-
imately 2-fold greater than that of nonsmok-
ers. EROD activities in heavy smokers were
further increased by a factor of four com-
pared to those of moderate smokers. 
A two-way analysis of variance (R2 = 0.56,
p < 0.001) showed that EROD activity was
related to smoking status during pregnancy (p
< 0.001), but not to the study group to which
women belonged (p = 0.42), suggesting that
smoking was the main determinant of EROD
activity variation. An analysis of covariance
carried out in the Nunavik group only (R2 =
0.52, p < 0.001) revealed that the relation ini-
tially found between placental EROD activity
and PCB 153 in simple correlation analysis
was no longer statistically significant when
tobacco smoke exposure was accounted for,
and that the latter explained most of the vari-
ability in EROD activity (p < 0.001). Further
analyses showed that the mean PCB 153
plasma concentration in smokers was greater
than that in nonsmokers of the Nunavik
group (mean difference = 1.28 ng/g lipids, p =
0.01). Furthermore, cotinine concentration in
meconium was correlated with PCB 153
plasma concentration (Spearman’s r = 0.42, p
= 0.011) in this group. Smoking was not
related to PCB 153 plasma concentration in
the southern Québec group.
Discussion
The objective of the present study was to
determine if placental CYP1A1 activity, a
potential marker of adverse developmental
effects, was related to dietary PCB exposure
in the Inuit population of Nunavik. The
potential confounding effect of tobacco
smoking was accounted for in the analysis
because it is known to modulate placental
CYP1A1 activity. Our results demonstrate
that PCB body burden does not signiﬁcantly
inﬂuence placental CYP1A1 activity, impli-
cating smoking during pregnancy as the
major modulating factor. 
Placental CYP1A1 induction has been
previously reported in women who smoked
during pregnancy (30,31,49) and further
related to lower birth weight (33). In the 
present study, the Nunavik and the reference
groups were similar with regard to several
maternal and newborn characteristics.
Smoking is more prevalent in the Nunavik
population than elsewhere in Québec (50), a
situation that made rigorous matching for
smoking status nearly impossible. However,
oversampling of smokers in the southern
Québec group and of nonsmokers in the
Nunavik group was performed to reach a bal-
anced study design, thereby allowing us to test
the effect of PCBs on CYP1A1 activity while
controlling for the effect of tobacco smoking.
Smoking status was further ascertained by the
use of cotinine concentration in meconium, a
biomarker previously validated (32), which led
to the reclassiﬁcation of several participants in
the appropriate smoking category. This
emphasizes the potential misclassiﬁcation bias
that may be induced by relying only on self-
declared cigarette consumption to determine
smoking status during pregnancy.
Body burden of PCBs observed in the
Nunavik study group, as assessed by umbilical
cord plasma concentrations expressed on a
lipid basis, was consistent with that docu-
mented in earlier reports (35,41), with con-
centrations of major PCB congeners being
approximately 4-fold higher in the Nunavik
group than in the southern Québec group.
Strong CYP1A1 inducers such as coplanar
PCBs (PCBs 77, 126, and 169) and PCDDs/
PCDFs could not be measured in the present
study due to the high volume of umbilical
cord plasma needed to conduct these analyses
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Table 4. Pearson’s correlation coefﬁcients between concentrations of various PCB congeners in umbilical
cord plasma from Nunavik neonates.
PCB 99 PCB 118 PCB 138 PCB 153 PCB 170 PCB 180 PCB 183
PCB 118 0.92 — — — — — —
PCB 138 0.92 0.88 — — — — —
PCB 153 0.90 0.85 0.99 — — — —
PCB 170 0.79 0.74 0.93 0.94 — — —
PCB 180 0.82 0.78 0.95 0.97 0.97 — —
PCB 183 0.77 0.76 0.81 0.79 0.77 0.80 —
PCB 187 0.83 0.82 0.94 0.95 0.93 0.96 0.81
aPearson’s r were calculated for congeners detected in > 70% of plasma and placental samples. All correlation coefﬁcients
were statistically signiﬁcant (p < 0.001).
Table 5. Classification of participants in smoking categories based on self-declared cigarette smoking
and after reclassiﬁcation based on cotinine concentration in meconium.
Southern Québec (n) Nunavik (n)
Self-declared smoking (cigarettes/day)
Nonsmokers (0) 15 12
Moderate smokers (1–10) 6 11
Heavy smokers (> 10) 9 12
Total 30 35
After reclassiﬁcation (cotinine, ng/g)
Nonsmokers (ND) 15 8
Moderate smokers (< 86) 6 10
Heavy smokers (≥ 86) 9 17
Total 30 35
ND, not detected.(at least 60 mL). However, strong correlations
(Pearson’s r = 0.98, p < 0.001) were previously
reported between total TEQs and either
total PCBs or PCB 153, using data from the
analysis of pooled plasma samples collected
from Inuit adults in the Nunavik population
(35,51). In this data set, PCB 153 was also
highly correlated with PCDD/PCDFs TEQs
(r = 0.85, p < 0.001) and to non-ortho PCBs
TEQs (r = 0.90, p < 0.001) (51). Furthermore,
strong intercorrelations were observed
among various PCB congeners in plasma,
including a strong correlation between PCB
153 and PCB 118 (a known AhR agonist),
in the present study (Table 4), as well as in
our ongoing infant cohort study in Nunavik
(40). Taken together, these lines of evidence
support the use of PCB 153 as a surrogate
marker of exposure to all organochlorines
present in the Arctic food chain, including
dioxin-like compounds. 
There was a nearly 2-fold difference in
PCB concentrations between cord plasma and
placental samples from the Nunavik group.
The higher concentrations of PCBs in cord
plasma could be explained by differences in
lipid composition between plasma and pla-
centa that may inﬂuence the distribution of
these lipophilic compounds. Nonetheless, con-
centrations of PCBs in umbilical cord plasma
were highly correlated with placental concen-
trations, further supporting the use of PCB
153 cord plasma concentrations to estimate
PCB concentrations in the fetal–placental unit.
Therefore, PCB 153 cord plasma concentra-
tion was used as the exposure variable to be
related to CYP1A1 activity in the placenta.
EROD activities measured in placental
samples of Inuit women were not signiﬁcantly
higher than those measured in the southern
Québec group, suggesting that the level of
exposure to dioxin-like compounds was not
high enough to induce placental CYP1A1
activity in this population. Nonetheless, sim-
ple correlation analysis showed a statistically
significant correlation of placental EROD
activity to PCB 153 plasma concentration in
the Nunavik group, an observation consistent
with the results of a previous study (48).
However, further analyses proved these initial
observations to be misleading. When tobacco
smoking during pregnancy was accounted for
in multivariate models, the inﬂuence of PCBs
on placental CYP1A1 activity in the Nunavik
group was no longer significant. In fact,
CYP1A1 activity was modulated by tobacco
smoke exposure, despite the relatively high
exposure to PCBs and dioxin-like compounds
in the Nunavik population. Hence, the
apparent correlation of CYP1A1 activity to
PCB 153 noted earlier was likely due to a
confounding effect of smoking. This interpre-
tation is supported by the statistically signiﬁ-
cant correlation noted between PCB 153
plasma concentration and cotinine concentra-
tion in meconium. Moreover, an association
between consumption of sea mammal fat and
tobacco smoking was reported among preg-
nant Inuit women in a recent study con-
ducted in the Nunavik population (50).
Increased placental CYP1A1 activity was
reported in women accidentally exposed to
high levels of PCBs and PCDFs (6,34).
However, the mean placental PCB 153 con-
centration in these women (Yu-Cheng
patients) was about 12-fold greater than
that reported here for the Nunavik group (8
ppb vs. 0.64 ± 0.02 ppb when converted to
wet weight) (34). Furthermore, because
Yu-Cheng patients were exposed to heat-
degraded PCBs containing PCDFs, exposure
to dioxin-like compounds is likely to be
much lower in the Nunavik population,
which is exposed to an environmental mix-
ture of PCBs with less AhR agonistic activity.
Decreased birth weights have been associ-
ated with high placental CYP1A1 activities in
women who smoked during pregnancy (33).
A similar association was noted in Yu-Cheng
women, suggesting an AhR-mediated mecha-
nism underlying the adverse developmental
effects of PCBs and PCDFs (34). In our
study, small sample sizes precluded an inves-
tigation of the possible relationship between
placental CYP1A1 activity and development
(birth weight). Whether placental CYP1A1
induction is related to developmental deﬁcits
in Inuit children will be investigated in an
ongoing study in Nunavik. However, based
on results from the present study, it appears
unlikely that PCBs found in the Arctic food
chain would be involved in such potential
adverse developmental effects through an
AhR-signaling pathway and placental
CYP1A1 induction.
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Figure 3. Placental EROD activity in Nunavik and
southern Québec groups by smoking categories.
Bars represent the GM and GSD; values shown
inside bars = n.
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